# Chemotherapy Combined With Bevacizumab Neoadjuvant Therapy for HER2-negative Breast Cancer

> **NCT05525767** · PHASE4 · RECRUITING · sponsor: **Hebei Medical University Fourth Hospital** · enrollment: 75 (estimated)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT05525767
- **Lead sponsor:** Hebei Medical University Fourth Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-03-31
- **Primary completion:** 2026-10-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2025-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05525767

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05525767, "Chemotherapy Combined With Bevacizumab Neoadjuvant Therapy for HER2-negative Breast Cancer". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05525767. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*